WHO’s Emergency Use Listing (EUL) assesses the quality, safety and efficacy of COVID-19 vaccines and is a prerequisite for COVAX Facility vaccine supply.
The Global Advisory Committee on Vaccine Safety, a group of experts that provides independent and authoritative guidance to the WHO on the topic of safe vaccine use, receives and assesses reports of suspected safety events of potentially international impact.
In October 2021, the GACVS COVID-19 subcommittee concluded that the mRNA COVID-19 vaccines have clear benefits in all age groups in reducing hospitalizations and deaths due to COVID-19.
8334
一种极其罕见的严重不良事件为心肌炎，这主要在接种第二剂疫苗后在18-35岁的年轻男性中观察到。
A very rare serious adverse event is myocarditis, which is mainly observed in young males aged 18-35 after the second dose.
These myocarditis cases typically occurred within a few days after vaccination, are generally mild, respond to conservative treatment, and are less severe with better outcomes than classical myocarditis or COVID-19 related myocarditis.
The Moderna vaccine after two doses and a first booster dose has been shown to have very high effectiveness against severe disease, hospitalizations and death, and modest effectiveness against symptomatic illness.